<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6324">
  <stage>Registered</stage>
  <submitdate>3/12/2015</submitdate>
  <approvaldate>3/12/2015</approvaldate>
  <nctid>NCT02623322</nctid>
  <trial_identification>
    <studytitle>A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults</studytitle>
    <scientifictitle>A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, Administered as Monotherapy for the Treatment of Acute Uncomplicated Seasonal Influenza A Infection in Otherwise Healthy Adults</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2016-000425-40</secondaryid>
    <secondaryid>GV29893</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Influenza A</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - MHAA4549A
Treatment: drugs - Placebo

Experimental: MHAA4549A: Dose Level 1 - Participants will receive single-dose MHAA4549A by intravenous (IV) administration.

Experimental: MHAA4549A: Dose Level 2 - Participants will receive single-dose MHAA4549A by IV administration.

Placebo Comparator: Placebo - Participants will receive single-dose placebo by IV administration.


Treatment: drugs: MHAA4549A
MHAA4549A will be administered as a single dose by IV administration.

Treatment: drugs: Placebo
Placebo will be administered as a single dose by IV administration.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percentage of Participants with Adverse Events (AEs)</outcome>
      <timepoint>From Baseline to Day 100</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants Requiring Hospitalization for Influenza-Related Complications</outcome>
      <timepoint>From Baseline to Day 100</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of Hospitalization for Influenza-Related Complications</outcome>
      <timepoint>From Baseline to Day 100</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants Requiring Antibiotics for Secondary Bacterial Infections</outcome>
      <timepoint>From Baseline to Day 100</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants with Complications of Influenza</outcome>
      <timepoint>From Baseline to Day 100</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants with Influenza A Relapse/Reinfection</outcome>
      <timepoint>From Baseline to Day 100</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area Under the Concentration-Time Curve (AUC) of MHAA4549A</outcome>
      <timepoint>Up to Day 100 (collections scheduled pre-dose [0 hours]; 60 minutes post-dose; and on Days 3, 5, 7, 30, and 100 post-dose; infusion duration = 2 hours)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum Serum Concentration (Cmax) of MHAA4549A</outcome>
      <timepoint>Up to Day 100 (collections scheduled pre-dose [0 hours]; 60 minutes post-dose; and on Days 3, 5, 7, 30, and 100 post-dose; infusion duration = 2 hours)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Alleviation of Symptoms of Influenza A Infection as Defined by a Rating of 1 or Less (Mild or None) for Each Symptom on a 4-Point Symptom Scale</outcome>
      <timepoint>From Baseline to Day 14</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants with Influenza-Related Deaths</outcome>
      <timepoint>From Baseline to Day 100</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Otherwise healthy adults

          -  Positive test for influenza A infection

          -  No more than 72 hours elapsed between onset of influenza-like illness and start of
             study drug

          -  Presence of at least one moderate or severe constitutional symptom such as headache,
             myalgia, fever, chills, fatigue, anorexia, or nausea PLUS one moderate or severe
             respiratory symptom such as cough, sore throat, or rhinorrhea

          -  For women of childbearing potential: negative pregnancy test and agreement to use
             acceptable contraceptive methods for at least 120 days after study drug administration

          -  For men: agreement to use acceptable contraceptive methods for at least 30 days after
             study drug administration</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Creatinine clearance less than or equal to (&lt;/=) 80 milliliters per minute (mL/min)

          -  Any significant medical conditions or laboratory abnormalities

          -  Clinical signs and symptoms consistent with otitis, bronchitis, sinusitis, or
             pneumonia or active bacterial infection

          -  Use of antiviral therapy in the period from onset of influenza-like illness and prior
             to enrollment

          -  Pregnancy at Screening or is currently pregnant or breastfeeding

          -  Investigational therapy within 30 days or 5 half-lives prior to start of study drug,
             whichever is greater

          -  Prior anti-influenza monoclonal antibody use

          -  Receipt of a nasal influenza A vaccine within 14 days prior to Screening

          -  Positive test for influenza B or influenza A+B within 2 weeks prior to study drug

          -  History of significant tobacco use or drug/alcohol abuse

          -  Chronic use of oral or inhaled corticosteroids within 30 days prior to Screening

          -  Autoimmune disease, known immunodeficiency of any cause, or use of immunosuppressive
             medications

          -  History of any chronic respiratory condition

          -  Human immunodeficiency virus (HIV) with cluster of differentiation (CD) 4 count &lt;/=
             200 cells per milliliter (cells/mL) in the past 12 months

          -  Serious infection requiring oral or IV antibiotics within 14 days prior to Screening</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>4/03/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>141</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>20/11/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Montana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>New Brunswick</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Anyang-si</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Bucheon-si,</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Incheon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Wonju</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Dunedin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Tauranga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Centurion</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Durban</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Groenkloof</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Johannesburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Kempton Park</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Klerksdorp</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Krugersdorp</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Lyttleton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Pretoria Gauteng Province</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Pretoria-West</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Queenswood</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Soweto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Welkom</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Islas Baleares</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>La Rioja</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Vizcaya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Guildford</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Middlesborough</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Genentech, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a Phase 2, randomized, double-blind, placebo-controlled single dose study in
      otherwise healthy adults with acute uncomplicated seasonal influenza A to assess the safety
      and tolerability, efficacy, and pharmacokinetics of MHAA4549A.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02623322</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>